Background:
Cystic fibrosis (CF) pulmonary exacerbations (PEx) are associated with a
significant drop in pulmonary function. The clinical value of measuring
bronchodilator (BD) responsiveness during treatment for PEx to monitor
or predict recovery of lung function is unclear.